Ovid Therapeutics

Ovid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7, 2023, at 9:30 a.m. ET.

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs. The Company also announced changes to its administrative functions intended to enhance efficiency and reduce costs.

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that the company was added to the Russell 3000® Index, effective after the U.S. market opens on June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.

Ovid Therapeutics Added to Russell 3000® Index

Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). Significant Revenue Potential. The median annual cost of orphan-designated therapy is approximately $218,000. The estimated total addressable market for TAK-935 includes approximately 159,000 patients with DS and LGS across the US, EU, and Japan.

Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results

NEW YORK, May 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March 31, 2023.

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) --  Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, and Graviton Bioscience Corporation, a privately held early-stage drug development company specializing in therapeutics that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), today announced a collaboration agreement to innovate novel medicines that they believe will significantly change the treatment paradigm for serious, rare neurological diseases.

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neurology (AAN) from ENDYMION 1, a long-term, open label extension study evaluating the effects of soticlestat on patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The findings reaffirm soticlestat was generally safe and well tolerated. Soticlestat additionally showed an encouraging median seizure reduction in both conditions.

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a  biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET.

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a fireside chat at the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023 at 4:00 p.m. ET.

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced the publication of multiple preclinical studies of OV350 in Cell Reports Medicine. The preclinical studies indicate that OV350 directly activates the potassium chloride cotransporter isoform 2 target, known as KCC2, and suggest that OV350 confers therapeutic efficacy in resistant epilepsy models and may offer a neuroprotective benefit.

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference in Boston, Massachusetts on March 6, 2023, at 12:50 p.m. ET.

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, is expanding its medical and development team with the respective appointments of industry veterans, Manoj Malhotra, M.D., as its Chief Medical Officer and Toshiya Nishi, D.V.M., as its Head of Epilepsy Research.

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the Ladenburg Thalmann 2022 Healthcare Conference in New York, New York on Thursday, September 29, 2022, at 9:00 a.m. ET.

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the second quarter ended June 30, 2022.

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, presented data at the 2022 Epilepsy Foundation Pipeline Conference. New preclinical data support the robust anti-seizure activity of OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor in development for rare adult and pediatric epilepsies.

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the first quarter ended March 31, 2022.

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

AbCellera Biologics

SIGA Technologies

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace.

3 Biotech Stocks Under $10 to Add to Your Buy List

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. ET.

News for Ovid Therapeutics Stock (OVID)